exelixis inc genomicsbased drug discovery company located alameda california producer cometriq treatment approved us food drug administration fda medullary thyroid cancer clinical activity several types metastatic cancer exelixis founded scientific founders spyridon yale time corey goodman gerry rubin university california george scangos joined company ceo business plan use model organisms fruit flies nematodes zebrafish functional genomics identify pathways biological targets could exploited fields agriculture medicine eventually set subsidiary exelixis plant sciences agricultural left radical exploratory phase behind became focused drug discovery chemical library million company went public year withdrawing offering week raised million company signed broad alliance gsk discover new drugs fields cancer inflammatory diseases vascular conditions gsk paid million cash bought million stock twice market rate committed providing exelixis million research funding also offered loan financing company limited internal efforts cancer settled strategy discovering developing drugs could inhibit targeted small sets tyrosine kinases needed cancer formation growth metastasis sets tks identified means prior functional genomics work approach controversial time companies try selectively target one protein discovery exelixis partnered daiichi sankyo compounds targeted mineralocorticoid receptors esaxerenone part company partnered mek inhibitor program genentech cobimetinib time part collaboration exelixis filed ind prior partnership committed funding running phase trial retained rights comarket company partnered lead cancer drug candidate would become called cabozantinib another cancer candidate bristol myers squibb bms returned rights exelixis returned rights drug candidate scangos departed ceo take company appointed michael morrissey president ceo morrissey joined company vice president discovery time company eight drugs clinical exelixis first drug approval came cabozantinib approved medullary thyroid cancer orphan approved europe exelixis invested heavily exploring cabozantinib cancers betting future company drug drug failed phase iii trial prostate cancer company laid genentech exelixis fda approval cobimetinib certain forms march exelixis licensed ipsen worldwide rights outside us canada japan market april fda granted approval marketing tablet formulation second line treatment kidney approved europe october december fda granted approval use cabozantinib first line treatment kidney may approval firstline treatment approved httpsenwikipediaorgwikiexelixis